Hemorrhagic problems in obstetrics, exclusive of disseminated intravascular coagulation

Hematology/Oncology Clinics of North America

Volumn 14, Issue 5, 2000, Pages 1171-1182

  Nizzi Jr , Frank A ^b   Mues, Gabriele ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; THROMBOCYTE CONCENTRATE; VON WILLEBRAND FACTOR;

BLEEDING DISORDER; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; GENETIC DISORDER; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOMODULATION; MATERNAL MORBIDITY; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; POSTPARTUM HEMORRHAGE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; VON WILLEBRAND DISEASE;

EID: 0033831722     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0889-8588(05)70177-5     Document Type: Review

References (68)

1. The problem of diagnosing von Willebrand's disease
2. Acquired factor VIII inhibitors - Successful treatment with an oral outpatient regimen
3. Von Willebrand's disease: A critical review
4. The platelet function analyzer (PFA-100): A novel in-vitro system for evaluation of primary haemostasis in children
5. The release of plasminogen activator and factor VIII by LVP, AVP, DDAVP, AT III and OT in man
6. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation
7. Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein IB induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation
8. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin
9. Obstetric and gynecologic patients with von Willebrand's disease
10. Use of a novel platelet function analyzer (PFA-100(TM)) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders
11. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: Results of an international survey
12. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases
13. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy
14. The effect of ABO blood group on the diagnosis of von Willebrand disease
15. Control of hemorrhage in von Willebrand's disease and a hemophiliac carrier with norethynodrel-mestranol
16. A survey of 215 non-hemophiliac patients with inhibitors to factor VIII
17. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies
18. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin-but not botrocetin-mediated binding of von Willebrand factor to platelets
19. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand's disease
20. Frequency of inherited bleeding disorders in women with menorrhagia
21. Pregnancy in women with von Willebrand's disease or factor XI deficiency
22. Factor VIII inhibitors - An algorithmic approach to treatment
23. The treatment of acquired factor VIII inhibitors: Worldwide experience with porcine factor VIII concentrate. International acquired hemophilia study group
24. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor
25. Von Willebrand's disease and pregnancy
26. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors
27. Effect of a factor VIII concentrate on type IIb von Willebrand's disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers
28. Treatment of acquired hemophilia
29. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P(TM)) in patients with von Willebrand disease
30. Screening and diagnosis of coagulation disorders
31. Impaired intracellular transport produced by a subset of Type IIA von Willebrand disease mutations
32. PFA-100(TM) system: A new method for assessment of platelet dysfunction
33. Genetics of classic von Willebrand's disease. I. Phenotypic variation within families
34. Prevalence of Von Willebrand's disease among U.S. adults
35. Fetal periventricular hemorrhage in von Willebrand's disease: Short review and first case presentation
36. Congenital hypofibringenemia and recurrent placental abruption
37. Reviews in molecular medicine
38. New variant of von Willebrand disease with defective binding to factor VIII
39. Von Willebrand's disease in pregnancy
40. A study of coagulation factor levels in women during labour and in their newborn infants
41. Skewed X chromosome inactivation in a female with hemophilia B and in her non-carrier daughter: A genetic influence on X chromosome inactivation?
42. Identification of platelet glycoprotein IIb/IIIa as the major binding site for released platelet-von Willebrand factor
43. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene
44. Von Willebrand disease: Recent advances in pathophysiology and treatment
45. Menstruation in hereditary bleeding disorders
46. Pregnancy in von Willebrand's disease
47. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease
48. Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VIII: C inhibitor
49. Epidemiological investigation of the prevalence of von Willebrand's disease
50. Von Willebrand factor
51. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease
52. A revised classification of von Willebrand disease: For the subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
53. Molecular mechanism and classification of von Willebrand disease
54. Assessment of changes in coagulation in parturients with preeclampsia using thromboelastography
55. Studies of the pathophysiology and treatment of von Willebrand's disease. VI. Variant von Willebrand's disease complicating placenta previa
56. Type IB von Willebrand's disease and pregnancy: Comparison of analytical methods of von Willebrand factor for classification of von Willebrand's disease subtypes
57. Laboratory diagnosis of von Willebrand's disease
58. Severe thrombocytopenia in a pregnant patient with platelet-associated IgM, and known von Willebrand's disease; a case report
59. Normal pregnancy in a patient with a postpartum factor VII inhibitor
60. Factor VIII and von Willebrand factor
61. Hereditar pseudohaumofilie
62. Investigation and management of haemorrhagic disorders in pregnancy
63. Successful management of pregnancy in a patient with von Willebrand disease Normandy
64. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate
65. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation
66. Prevalence of von Willebrand disease in children: A multiethnic study
67. Prenatal and molecular diagnosis of hemophilia B
68. Subunit composition of plasma in von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE)